-
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with consistent responses that are higher than those observed in trials of competing agents at the end of their respective parental trials Namely, ~67% of patients treated with SLK…
-
World Regional Anaesthesia and Pain Medicine day Workshop brings the Spotlight on Strengthening Patient Safety Standards
New Delhi, Delhi, India BD (Becton, Dickinson and Company) recently participated as Knowledge Partner at the World Regional Anaesthesia & Pain Medicine (RAPM) Day Workshop. With the objective of reinforcing patient-safety practices in Regional Anaesthesia, BD India/South Asia focused on enabling real-time, hands-on learning for clinicians to advanced spinal anaesthesia solutions and supporting faculty-led live…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
